MARKER THERAPEUTICS, INC. Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)
MARKER THERAPEUTICS, INC. (MRKR) reported Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) of $58.33 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-04-15.
Discontinued › Notes
us-gaap:CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease · last filed 2015-04-15
- MARKER THERAPEUTICS, INC. cumulative translation adjustment, net of tax, period increase (decrease) for the quarter ending 2014-12-31 was $55.57K, a 3577.63% increase year-over-year.
- MARKER THERAPEUTICS, INC. cumulative translation adjustment, net of tax, period increase (decrease) for the quarter ending 2014-09-30 was $2.97K.
- MARKER THERAPEUTICS, INC. cumulative translation adjustment, net of tax, period increase (decrease) for the quarter ending 2014-06-30 was $1.04K, a 77.58% decline year-over-year.
- MARKER THERAPEUTICS, INC. cumulative translation adjustment, net of tax, period increase (decrease) for the quarter ending 2014-03-31 was -$1.25K.
- MARKER THERAPEUTICS, INC. cumulative translation adjustment, net of tax, period increase (decrease) for fiscal 2014 was $58.33K, a 1660.23% increase from fiscal 2013.
- MARKER THERAPEUTICS, INC. cumulative translation adjustment, net of tax, period increase (decrease) for fiscal 2013 was $3.31K.
| Period end | Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 3 month | Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 6 month | Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 9 month | Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 12 month | Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 173 month | Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease) 179 month |
|---|---|---|---|---|---|---|
| 2014-12-31 | $55.57K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-15 | $58.54K derived: sum of 2 quarters · filed 2015-04-15 | $59.58K derived: sum of 3 quarters · filed 2015-04-15 | $58.33K 10-K · filed 2015-04-15 | ||
| 2014-09-30 | $2.97K 10-Q · filed 2014-11-19 | $4.01K derived: sum of 2 quarters · filed 2014-11-19 | $2.77K 10-Q · filed 2014-11-19 | $4.28K derived: sum of 4 quarters · filed 2015-04-15 | ||
| 2014-06-30 | $1.04K 10-Q · filed 2014-08-18 | -$207.00 10-Q · filed 2014-08-18 | $1.30K derived: sum of 3 quarters · filed 2015-04-15 | -$98.00 derived: sum of 4 quarters · filed 2015-04-15 | -$58.54K 10-Q · filed 2014-08-18 | |
| 2014-03-31 | -$1.25K 10-Q/A · filed 2014-05-21 | $262.00 derived: sum of 2 quarters · filed 2015-04-15 | -$1.14K derived: sum of 3 quarters · filed 2015-04-15 | $3.51K derived: sum of 4 quarters · filed 2015-04-15 | ||
| 2013-12-31 | $1.51K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-15 | $109.00 derived: sum of 2 quarters · filed 2015-04-15 | $4.76K derived: sum of 3 quarters · filed 2015-04-15 | $3.31K 10-K · filed 2015-04-15 | -$56.14K 10-Q/A · filed 2014-05-21 | |
| 2013-09-30 | -$1.40K 10-Q · filed 2014-11-19 | $3.25K derived: sum of 2 quarters · filed 2014-11-19 | $1.80K 10-Q · filed 2014-11-19 | |||
| 2013-06-30 | $4.65K 10-Q · filed 2014-08-18 | $3.21K 10-Q · filed 2014-08-18 | ||||
| 2013-03-31 | -$1.44K 10-Q/A · filed 2014-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |